Incyte will not start its planned Phase 3 ovarian cancer study of INCB123667, removing a planned chance to test the drug. The choice was not based on safety or efficacy results, and Incyte expects no change to its financial forecast or long-term outlook, but the study is still gone.
This removes a planned chance to test INCB123667 in ovarian cancer. Incyte said the choice was not based on safety or efficacy results, and its financial forecast and long-term outlook stay unchanged. Those facts limit the concern, but the planned study is still gone.
Follow Incyte Corporation (INCY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for INCY